Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Trends and Future Outlook to 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What CAGR And Valuation Are Anticipated For The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
The treatment market for transthyretin amyloid cardiomyopathy (attr-cm) has seen a significant increase in size in the recent past. Its growth is set to continue, rising from a value of $10.36 billion in 2024 to an elevated value of $13.29 billion by 2025, showcasing a remarkable compound annual growth rate (CAGR) of 28.2%. The surge witnessed during the preceding years can be linked to the growing cases of transthyretin amyloid cardiomyopathy, increased incidents of transthyretin amyloidosis in elderly patients, elevated awareness among medical professionals and their patients, along with the enhanced understanding and progress in healthcare amenities.
The market for transthyretin amyloid cardiomyopathy (attr-cm) treatment is predicted to experience considerable expansion in the coming years. It’s anticipated to rise to $35.5 billion by 2029, with a compound annual growth rate (CAGR) of 27.8%. The projected growth can be credited to factors such as the rising incidence of transthyretin amyloidosis, the increased detection rate of neuropathic conditions, the growing elderly demographic, the escalating demand for specific medications to manage symptoms of this rare disease, and the overall upsurge in healthcare demand. The forecast period also showcases major trends such as novel diagnostic methods, the advent of innovative therapeutic management techniques, focused treatments for transthyretin amyloidosis, advancements in diagnostic approaches, and cardiac MRI techniques.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp
What Are The Primary Factors Supporting The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Expansion?
The increasing occurrence of chronic diseases, which are enduring conditions that advance gradually over a year or more requiring sustained medical care, is predicted to drive the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market. This rise can be linked to factors like aging populations, inactive lifestyles, unhealthy eating habits, higher obesity levels, and environmental pollution exposure. Transthyretin amyloid cardiomyopathy treatment aids by stabilizing transthyretin, lessening amyloid accumulation, enhancing heart performance, and relieving symptoms to manage associated chronic conditions better. For example, in September 2023, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported 41 million death toll, 74% of which were due to non-communicable diseases (NCDs) or chronic diseases annually. Around the world, deaths from cardiovascular diseases were 17.9 million, from cancer – 9.3 million, from chronic respiratory diseases – 4.1 million, and from diabetes – 2.0 million. Consequently, the upward trend in chronic diseases incidence continues to fuel the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
Which Segments Define The Structure Of The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
The transthyretin amyloid cardiomyopathy (attr-cm) treatmentmarket covered in this report is segmented –
1) By Type: Transthyretin Stabilizers; Nonsteroidal Anti-inflammatory Drugs (NSAID); RNAi Therapy; Other Types
2) By Indication: Wild type ATTR Amyloidosis; Hereditary ATTR amyloidosis
3) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Transthyretin Stabilizers: Tafamidis; Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin; Ibuprofen; Other NSAIDs
3) By RNAi Therapy: Patisiran; Vutrisiran
4) By Other Types: Gene Silencing Therapies; Immunotherapy Approaches; Emerging Small Molecule Therapies
What Strategic Shifts And Innovations Are Influencing The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Leading companies in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are developing innovative therapies, including oral prescription medications that stabilize transthyretin (TTR) proteins or reduce amyloid fibril accumulation in the heart. Oral prescription medications are drugs prescribed by healthcare providers, administered by mouth in tablet, capsule, or liquid forms. For example, in November 2024, BridgeBio Pharma Inc., a US biotech company, received FDA approval for Attruby (acoramidis) to treat adults with ATTR-CM. This drug stabilizes TTR proteins, lowering risks of heart-related deaths and hospitalizations. Clinical trials have demonstrated it is well-tolerated and provides rapid benefits by addressing the disease’s root cause.
Who Are The Primary Market Leaders In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG
Access The Complete Report Here:
What Regional Factors Are Accelerating Growth In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21304&type=smp
Browse Through More Reports Similar to the Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market 2025, By The Business Research Company
Cardiovascular Surgery Devices And Equipment Global Market Report 2025
Cardiovascular Monitoring And Diagnostic Devices And Equipment Global Market Report 2025
Interventional Cardiology Devices And Equipment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
